Valiant Laboratories (NSE:VALIANTLAB) Other Long-Term Liabilities: ₹46 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VALIANTLAB Valiant Laboratories Ltd NSE:VALIANTLAB
51 GF Score
Price ₹60.37
GF Value ₹101.33
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Valiant Laboratories Other Long-Term Liabilities?

Valiant Laboratories NSE:VALIANTLAB -1.85% 51 Other Long-Term Liabilities is ₹46 Mil as of Mar. 2026. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹101.33 (Possible Value Trap). The stock has 5 warning signs investors should review.

Valiant Laboratories's other long-term liabilities for the quarter that ended in Mar. 2026 was ₹46 Mil.

Valiant Laboratories's quarterly other long-term liabilities declined from Sep. 2025 (₹26 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹46 Mil).

Valiant Laboratories's annual other long-term liabilities increased from Mar. 2024 (₹16 Mil) to Mar. 2025 (₹22 Mil) and increased from Mar. 2025 (₹22 Mil) to Mar. 2026 (₹46 Mil).

Valiant Laboratories Other Long-Term Liabilities Related Terms

Valiant Laboratories Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Valiant Laboratories's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valiant Laboratories Other Long-Term Liabilities Chart

Valiant Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial 12.58 16.28 15.79 22.03 46.09

Valiant Laboratories Quarterly Data
Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.03 0.00 25.69 0.00 46.09
NSE:VALIANTLAB
51GF Score
Valiant Laboratories Ltd NSE:VALIANTLAB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valiant Laboratories Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹46 Mil mean?
Valiant Laboratories (NSE:VALIANTLAB) has a Other Long-Term Liabilities of ₹46 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Valiant Laboratories and its competitors.
Is Valiant Laboratories' Other Long-Term Liabilities too high?
Valiant Laboratories' current Other Long-Term Liabilities is ₹46 Mil. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Other Long-Term Liabilities compare to ZTS?
Valiant Laboratories' Other Long-Term Liabilities of ₹46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Valiant Laboratories and its competitors. Valiant Laboratories's current Other Long-Term Liabilities is ₹46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹101.33, compared to a current price of ₹60.37 — trading 40.4% below its estimated fair value. The current Other Long-Term Liabilities is ₹46 Mil. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Other Long-Term Liabilities is ₹46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued. The current stock price of ₹60.37 is trading 40.4% below its estimated GF Value™ of ₹101.33. GuruFocus considers Valiant Laboratories to be Possible Value Trap.

Key valuation signals for NSE:VALIANTLAB:

  • Other Long-Term Liabilities: ₹46 Mil
  • GF Value™: ₹101.33 vs. price of ₹60.37 (40.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valiant Laboratories Business Description

Other Exchanges 543998:India
Address Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score

Get the complete analysis for NSE:VALIANTLAB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹60.37
Price
₹101.33
GF Value